|1.||Marton, Laurence J: 2 articles (12/2008 - 11/2006)|
|2.||Sobolewski, Michelle: 1 article (12/2008)|
|3.||Casero, Robert A: 1 article (12/2008)|
|4.||Hacker, Amy: 1 article (12/2008)|
|5.||Akiyama, Hideo: 1 article (11/2006)|
|6.||Khu, Naw Htee: 1 article (11/2006)|
|7.||Campochiaro, Peter A: 1 article (11/2006)|
|8.||Lima e Silva, Raquel: 1 article (11/2006)|
|9.||Hackett, Sean F: 1 article (11/2006)|
|10.||Gong, Yuan Yuan: 1 article (11/2006)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2008 - "Finally, the in vivo efficacy of CGC-11047 in the treatment of a nude mouse model of human non-small cell lung cancer was evaluated. "
12/01/2008 - "The greatest biochemical effects were observed in the non-small cell lung cancer cells where in addition to a profound down regulation of ODC activity, there was a significant increase in polyamine catabolism leading to a greater degree of polyamine pool depletion and greater accumulation of CGC-11047 when compared with the changes observed for the small cell lines. "
12/01/2008 - "CGC-11047 effectively inhibited the growth of both small cell and non-small cell lung cancer cells in vitro. "
12/01/2008 - "In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells."
12/01/2008 - "Importantly, CGC-11047 was found to be highly significant (P < 0.0001) in delaying the progression of established tumors in an in vivo model of human non-small cell lung cancer. "
|5.||Lung Neoplasms (Lung Cancer)
12/01/2008 - "CGC-11047 represents a promising new polyamine analogue that warrants further preclinical and, potentially, clinical evaluation in lung cancer."
12/01/2008 - "Human lung cancers cell lines representing non-small cell and small cell lung cancers were investigated for their growth and biochemical response to CGC-11047. "